Multistage investment, systematic risk premium and CAPM beta: empirical evidence from product development

References

• Berk , JB , Green , RC and Naik , V . 2004 . Valuation of return dynamics of new ventures . The Review of Financial Studies , 17 : 1 – 35 .
   Web of Science ®Google Scholar
• Berman , J and Pfleeger , J . 1997 . Which industries are sensitive to business cycle? Monthly Labor Review, Bureau of Labor Statistics, February 1997
   Google Scholar
• Cornell , B . 1999 . Risk, duration, and capital budgeting: new evidence on some old questions . Journal of Business , 72 : 183 – 99 .
   Web of Science ®Google Scholar
• Cummins , JD and Phillips , RD . 2005 . Estimating the cost of equity capital for property-liability insurers . Journal of Risk and Insurance , 72 : 441 – 78 .
   Web of Science ®Google Scholar
• DiMasi , JA . 1995 . Success rates for new drugs entering clinical testing in the United States . Clinical Pharmacology and Therapeutics , 58 : 1 – 13 .
   PubMed Web of Science ®Google Scholar
• DiMasi , JA , Hansen , RW and Grabowski , HG . 2003 . The price of innovation: new estimates of drug development costs . Journal of Health Economics , 22 : 151 – 81 .
   PubMed Web of Science ®Google Scholar
• Dimson , E . 1979 . Risk measurement when shares are subject to infrequent trading . Journal of Financial Economics , 7 : 197 – 226 .
   Web of Science ®Google Scholar
• Ehrhardt , MC and Bhagwat , YN . 1991 . A full-information approach for estimating divisional betas . Financial Management , 20 : 60 – 9 .
   Web of Science ®Google Scholar
• Fama , EF and French , KR . 1992 . The cross-section of expected stock returns . Journal of Finance , 47 : 427 – 65 .
   Web of Science ®Google Scholar
• Fama , EF and French , KR . 1997 . Industry cost of equity . Journal of Financial Economics , 39 : 3 – 56 .
   Google Scholar
• Giaccotto , C , Golec , J and Vernon , J . 2011 . New estimates of the cost of capital for pharmaceutical firms . Journal of Corporate Finance , 17 : 526 – 40 .
   Web of Science ®Google Scholar
• Graham , JR and Harvey , CR . 2001 . Theory and practice of corporate finance: evidence from the field . Journal of Financial Economics , 60 : 187 – 243 .
   Web of Science ®Google Scholar
• Jagannathan , R and Meier , I . 2002 . Do we need CAPM for capital budgeting? . Financial Management , 31 : 55 – 77 .
   Web of Science ®Google Scholar
• Jagannathan , R . 2011 . Meier, I. and Tarhan, V. , The cross-section of hurdle rate for capital budgeting: an empirical analysis of survey data, NBER Working Paper No. 16770, National Bureau of Economic Research, Cambridge, MA
   Google Scholar
• Kaplan , PD and Peterson , JD . 1998 . Full-information industry betas . Financial Management , 27 : 85 – 93 .
   Web of Science ®Google Scholar
• Myers , SC and Howe , CD . 1997 . A life-cycle model of pharmaceutical R&D Technical Report, No. WP#41-97, Massachusetts Institute of Technology
   Google Scholar
• Myers , SC and Shyam-Sunder , L . 1996 . “ Cost of capital estimates for pharmaceutical research and development ” . In Competitive Strategies in the Pharmaceutical Industry , Edited by: Helms , RB . 208 – 37 . Washington , DC : American Enterprise Institute .
   Google Scholar
• Puran , S . 2005 . The valuation of part-developed projects in the pharmaceutical sector Dissertation, Fitzwilliam College
   Google Scholar
• Scholes , M and Williams , J . 1977 . Estimating betas from nonsynchronous data . Journal of Financial Economics , 5 : 309 – 27 .
   Web of Science ®Google Scholar
• Spilker , B . 1999 . The Drug Development and Approval Process , Washington , DC : Pharmaceutical Research and Manufacturers of America .
   Google Scholar
• Trigeorgis , L . 1996 . Real Options , Cambridge, MA; London : MIT Press .
   Google Scholar